English, PDF, 1,816kb
Recommendations to OECD Ministers of Health from the High-Level Reflection Group on the Future of Health Statistics: Strengthening the international comparison of health system performance through patient-reported indicators.
This report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money. The analysis considers how health systems and policy makers should adapt in terms of development, assessment and uptake of health technologies. The first chapter provides an examination of adoption and impact of medical technology in the past and how health systems are preparing for continuation of such trends in the future. Subsequent chapters examine the need to balance innovation, value, and access for pharmaceuticals and medical devices, respectively, followed by a consideration of their combined promise in the area of precision medicine. The final chapter examines how health systems can make better use of health data and digital technologies. The report focuses on opportunities linked to new and emerging technologies as well as current challenges faced by policy makers, and suggests a new governance framework to address these challenges.
OECD Health Care Quality Reviews seek to examine what works and what does not work in different countries – both to benchmark the efforts of countries and to provide advice on reforms to improve their health system.
Following a brief pause after the economic crisis, health expenditure is rising again in most OECD countries. Yet, a considerable part of this health expenditure makes little or no contribution to improving people's health. In some cases, it even results in worse health outcomes. Countries could potentially spend significantly less on health care with no impact on health system performance, or on health outcomes. This report systematically reviews strategies put in place by countries to limit ineffective spending and waste. On the clinical front, preventable errors and low-value care are discussed. The operational waste discussion reviews strategies to obtain lower prices for medical goods and to better target the use of expensive inputs. Finally, the report reviews countries experiences in containing administrative costs and integrity violations in health.
The policy study published by the OECD is based on six case studies, an extensive review of the literature, and analysis of relevant data. The report provides context for the analysis of pharmaceutical pricing policies in OECD countries, describes pricing policies employed by the OECD zone and assesses their impact.
The Working Paper sheds light on the extent to which “value” is considered in pricing and/or coverage decisions in 14 OECD member countries. It describes methods used by countries to assess the therapeutic benefits of new products, as well as approaches for economic evaluation, where relevant, and aims to illustrate how value is assessed and what is its impact on pricing and/or reimbursement decisions.
English, PDF, 2,042kb
Access key results from "Health at a Glance Europe 2016" in this chartset.
English, PDF, 766kb
Gli indicatori di stato di salute e qualità dell’assistenza in Italia rimangono fra i migliori in UE. La percentuale di popolazione che riporta esigenze di cure mediche e dentali non soddisfatte è in crescita, in particolare per i gruppi a basso reddito, con un conseguente potenziale aumento delle disuguaglianze nel settore sanitario.
Français, PDF, 1,216kb
Présentation en français sur les résultats clés issus du Panorama de la santé Europe 2016 : "Comment la France se compare".
English, PDF, 674kb
Germany is the EU country that spends the most on health, allocating 11.1% of its GDP to health expenditure in 2015. Recent health spending trends closely follow economic growth, with an annual increase of around 2%.